New antifungal drug put to the test in healthy volunteers
NCT ID NCT02956499
First seen Oct 31, 2025 · Last updated May 07, 2026 · Updated 25 times
Summary
This early-stage study tested the safety and tolerability of a new antifungal drug called APX001 in 200 healthy adults. Participants received either the drug or a placebo by IV infusion, and researchers monitored for side effects and how the drug moved through the body. The goal was not to treat any disease, but to gather essential safety data before testing in patients with fungal infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PRA Health Sciences
Groningen, 9728 NZ, Netherlands
-
PRA Health Sciences
Groningen, Netherlands
Conditions
Explore the condition pages connected to this study.